Natera reported fourth quarter 2025 revenue of $665.5 million, an increase of 39.8% year-over-year, driven by record test volumes and improvements in average selling price. For the full year 2025, the company generated revenue of $2.31 billion and achieved positive cash inflow of $107.6 million.
Key Highlights
- Fourth quarter revenue of $665.5 million surpassed analyst estimates, growing 39.8% from the prior year.
- The company processed approximately 233,300 oncology tests in the fourth quarter, a 54.7% year-over-year increase, confirming strong momentum in its molecular residual disease (MRD) testing business.
- Gross margin expanded to 66.9% from 62.9% in the same quarter last year, and the company guided for continued positive cash inflow in 2026.